Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?

Seminars in Liver Disease

Volumn 37, Issue 2, 2017, Pages 109-118

  Reig, María ^a   Boix, Loreto ^a   Mariño, Zoe ^a   Torres, Ferran ^b,c   Forns, Xavier ^a   Bruix, Jordi ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

direct antiviral agents; hepatitis C; hepatocellular carcinoma; incidence; recurrence

Indexed keywords

ANTIVIRUS AGENT; PLACEBO; SORAFENIB; TUMOR ANTIGEN;

ANTIVIRAL THERAPY; ARTICLE; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RISK; CHRONIC HEPATITIS C; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DISEASE ASSOCIATION; HEPATITIS C VIRUS; HUMAN; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; LIVER CANCER; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PUBLICATION; RECURRENCE RISK; STRESS; TUMOR IMMUNITY; TUMOR RECURRENCE; VIRAL CLEARANCE; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; LIVER TUMOR; PREDICTIVE VALUE; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR ESCAPE; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MONITORING, IMMUNOLOGIC; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR ESCAPE;

EID: 85017148657     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0037-1601349     Document Type: Article

References (52)

1. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C. J Hepatol: 2016; 66 01 153 194
2. Poordad F. Lawitz E. Kowdley K. V., et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med: 2013; 368 01 45 53
3. Ferenci P. Bernstein D. Lalezari J., et al. PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med: 2014; 370 21 1983 1992
4. Feld J. J. Kowdley K. V. Coakley E., et al. Treatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. N Engl J Med: 2014; 370 17 1594 1603
5. Kwo P. Y. Mantry P. S. Coakley E., et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med: 2014; 371 25 2375 2382
6. Foster G. R. Afdhal N. Roberts S. K., et al. ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med: 2015; 373 27 2608 2617
7. Curry M. P. O'Leary J. G. Bzowej N., et al. ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med: 2015; 373 27 2618 2628
8. Feld J. J. Jacobson I. M. Hézode C., et al. ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med: 2015; 373 27 2599 2607
9. Sulkowski M. S. Gardiner D. F. Rodriguez-Torres M., et al. AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med: 2014; 370 03 211 221
10. Poordad F. Hezode C. Trinh R., et al. ABT-450/rombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med: 2014; 370 21 1973 1982
11. Afdhal N. Reddy K. R. Nelson D. R., et al. ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med: 2014; 370 16 1483 1493
12. Jacobson I. M. Gordon S. C. Kowdley K. V., et al. POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med: 2013; 368 20 1867 1877
13. Lawitz E. Mangia A. Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med: 2013; 368 20 1878 1887
14. Calvaruso V. Craxì A. Why do I treat my patients with mild hepatitis C? Liver Int: 2016; 36 01 7 12
15. Reig M. Mariño Z. Perelló C., et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol: 2016; 65 04 719 726
16. Bruix J. Takayama T. Mazzaferro V., et al. STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol: 2015; 16 13 1344 1354
17. Ikeda K. Kobayashi M. Kawamura Y., et al. Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model. Liver Int: 2011; 31 05 692 699
18. Buonfiglioli F. Conti F. Andreone P., et al. Development of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Paper presented at: European Association for the Study of the Liver: The International Liver Congress; April 13-17, 2016; Barcelona, Spain. Abstract LBP 506. J Hepatol: 2016; 64 02 S215
19. Conti F. Buonfiglioli F. Scuteri A., et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol: 2016; 65 04 727 733
20. Cheung MC M. Walker A. J. Hudson B. E., et al. HCV Research UK. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol: 2016; 65 04 741 747
21. Foster G. R. Irving W. L. Cheung MC M., et al. Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol: 2016; 64 06 1224 1231
22. Zeng Q-L. Li Z-Q. Liang H-X., et al. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming? J Hepatol: 2016; 65 05 1068 1069
23. Zavaglia C. Okolicsanyi S. Cesarini L., et al. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? J Hepatol: 2017; 66 01 236 237
24. Tsai P-C. Huang C-F. Yu M-L. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: issue of the interval between HCC treatment and antiviral therapy. J Hepatol: 2017; 66 02 464
25. Kozbial K. Moser S. Schwarzer R., et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol: 2016; 65 04 856 858
26. ANRS Collaborative Study Group on Hepatocellular Carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol: 2016; 65 04 734 740
27. Sugimoto K. Kim S. R. Kim S. K., et al. Comparison of daclatasvir and asunaprevir for chronic HCV 1b infection with telaprevir and simeprevir plus peginterferon and ribavirin, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma. Oncology: 2015; 89 02 42 46
28. Ganne-Carrié N. Layese R. Bourcier V., et al. ANRS CO12 CirVir Study Group. Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology: 2016; 64 04 1136 1147
29. Kobayashi M. Suzuki F. Fujiyama S., et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol: 2017; 89 03 476 483
30. Petta S. Cabibbo G. Barbara M., et al. Italian Liver Cancer (ITA.LI.CA) Group. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther: 2017; 45 01 160 168
31. Torres H. A. Vauthey J. N. Economides M. P. Mahale P. Kaseb A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: first, do no harm by withdrawing treatment. J Hepatol: 2016; 65 04 862 864
32. Yang J. D. Aqel B. A. Pungpapong S. Gores G. J. Roberts L. R. Leise M. D. Direct acting antiviral therapy and tumor recurrence after liver transplant for hepatitis C-associated hepatocellular carcinoma. J Hepatol: 2016; 65 04 859 860. Doi: 10.1016/j.jhep.2016.06.023 Epub 2016 Jul 5
33. Toyoda H. Tada T. Takaguchi K., et al. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis. J Viral Hepat: 2017; 10.1111/jvh.12665
34. Minami T. Tateishi R. Nakagomi R., et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol: 2016; 65 06 1272 1273
35. Cammà C. Cabibbo G. Craxì A. Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J Hepatol: 2016; 65 04 861 862
36. Pol S. Bourliere M. Lucier S., et al. ANRS/AFEF HEPATHER study group. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J Hepatol: 2017; 66 01 39 47
37. Trinchet J-C. Bourcier V. Chaffaut C., et al. ANRS CO12 CirVir Group. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology: 2015; 62 03 737 750
38. Nahon P. Bourcier V. Layese R., et al. ANRS CO12 CirVir Group. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology: 2017; 152 01 142 156.e2
39. Cabibbo G. Petta S. Barbàra M., et al. ITA.LI.CA study group. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int: 2017; 10.1111/liv.13357
40. Alonso S. Riveiro-Barciela M. Fernandez I., et al. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. J Viral Hepat: 2017; 24 04 304 311
41. Romano A. Capra F. Piovesan S. Alberti A. Incidence and pattern of 'de novo' hepatocellular carcinoma in HCV patients treated with oral DAAs. Paper presented at: 67th Meeting of the American Association for the Study of Liver Diseases: Liver Meeting; November 11-15,: 2016;; Boston, MA. Abstract 19
42. Carat F. Clinical outcomes in HCV-infected patients treated with direct acting antivirals-18 months-post-treatment follow-up in the French ANRS CO22 HEPATHER cohort study. Paper presented at: European Association for the Study of the Liver: The International Liver Congress; April 13-17, 2016; Barcelona, Spain. Abstract LBP 505. J Hepatol: 2016; 64 02 S215
43. Iacobellis A. Siciliano M. Perri F., et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol: 2007; 46 02 206 212
44. European Medicines Agency. PRAC warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2016/12/news-detail-002659.jsp&mid=WC0b01ac058004d5c1. Accessed February 25, 2017
45. Fridman W. H. Pagès F. Sautès-Fridman C. Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer: 2012; 12 04 298 306
46. Quesnel B. Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells? Expert Rev Vaccines: 2006; 5 06 773 781
47. Galon J. Mlecnik B. Bindea G., et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol: 2014; 232 02 199 209
48. Dalai S. K. Khoruzhenko S. Drake C. G. Jie C. C. Sadegh-Nasseri S. Resolution of infection promotes a state of dormancy and long survival of CD4 memory T cells. Immunol Cell Biol: 2011; 89 08 870 881
49. Collins J. M. Raphael K. L. Terry C., et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis: 2015; 61 08 1304 1306
50. Perelló C. S. Fernández-Carrillo C. Londoño M-C., et al. Reactivation of herpes virus in patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol: 2016; 14 11 1662 1666. Doi: 10.1016/j.cgh.2016.05.016. Epub 2016 May 20
51. Manjili M. H. The inherent premise of immunotherapy for cancer dormancy. Cancer Res: 2014; 74 23 6745 6749
52. Sprinzl M. F. Reisinger F. Puschnik A., et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology: 2013; 57 06 2358 2368